Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Lilly Announces Plans to Close its Shanghai R&D Center

publication date: Sep 7, 2017

In a letter to China employees, Andrew Hodge, President, Lilly China, notified staff members that Lilly will close down its Shanghai R&D center. The center opened in 2012 and is located in Zhangjiang Hi-Tech Park. Dedicated to diabetes research, it currently has 200 employees. The closing is part of a larger global Lilly restructuring in which 3,500 Lilly employees will leave the company. In the last year, two of Lilly's late-stage pipeline drugs suffered setbacks. To pare down its development costs, the company plans to cut seven Phase II candidates and partner another ten mid-stage cancer drugs. Lilly will prioritize development of seven promising candidates. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.